<DOC>
	<DOC>NCT02545504</DOC>
	<brief_summary>The primary objective of this study is to compare the efficacy of andecaliximab (formerly GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.</brief_summary>
	<brief_title>Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Key Adults with histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction that is inoperable, locally advanced or metastatic and not amenable to curative therapy Adequate hematologic, liver, coagulation and kidney function Eastern Cooperative Oncology Group (ECOG) ≤ 1 Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 Key Previous chemotherapy for locally advanced or metastatic gastric cancer. Human Epidermal Growth Factor Receptor 2 (HER2)positive gastric cancer HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection Pregnant or breast feeding women Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids Grade ≥ 2 peripheral neuropathy Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastroesophageal junction (GEJ)</keyword>
	<keyword>Stomach cancer</keyword>
</DOC>